4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Inclusion Criteria:

1. Subjects must be able to understand and communicate with the investigator and comply
with the requirements of the study and must give a written, signed and dated informed
consent before any study related activity is performed. Where relevant, a legal
representative will also sign the informed consent according to local laws and
regulations.

2. Subjects who complete Week 52 of study CAIN457A2304 or complete Week 40 of study
CAIN457A2307

3. Subjects expected to benefit from participation in the extension study, as assessed by
the subject and investigator

Exclusion Criteria:

1. A protocol deviation in the core studies which according to the investigator will
prevent the meaningful analysis of the extension study for the individual subject

2. Ongoing use of prohibited psoriasis or non-psoriasis treatments. Time period from last
use of prohibited treatments in the core study to first dose of study drug in this
extension study.

3. Subjects expected to be exposed to an undue safety risk if participating in the trial

4. Current severe progressive or uncontrolled disease which in the judgment of the
investigator renders the subject unsuitable for the trial

5. Plans for administration of live vaccines during the study period

6. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
female after conception and until the termination of gestation, confirmed by a
positive hCG laboratory test (>10 mIU/mL).